Evidence map›Paper›PMID 22748108›Full record

ArticleNeuromodulation : journal of the International Neuromodulation Society

Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog.

Tony L Yaksh, Annelies de Kater, Robin Dean, Brookie M Best, George P Miljanich

Open access · greenAbstract read
In one paragraph

Article in Neuromodulation : journal of the International Neuromodulation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 52 citations in OpenAlex.

  1. Efficacy and safety of the CaPain reports · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Systemic antihyperalgesic effect of a novel conotoxin fromFrontiers in pain research (Lausanne, Switzerland) · 2024
    Article
  6. Article
  7. Review
  8. Effects of fadolmidine, an αPharmacology research & perspectives · 2021
    Article
  9. Analgesic and side effects of intravenous recombinant Phα1β.The journal of venomous animals and toxins including tropical diseases · 2020
    Article
  10. Article
  11. Review
  12. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.Neuromodulation : journal of the International Neuromodulation Society · 2016
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Tony L YakshDepartment of Anesthesiology, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. tyaksh@ucsd.edu
Annelies de Kater
Robin Dean
Brookie M Best
George P Miljanich
Cassava Sciences (United States) · USUniversity of California, San Diego · USUniversity of Montana · US

Funding

Characterization of Toxicity with Spinal OpiatesR01DA015353 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YAKSH, TONY L. · 2003 to 2017
$4.4M
NIDA NIH HHS R01 DA015353ONDIEH CDC HHS ND-15353
6 · The paper itself

Abstract

background and purposeZiconotide is a peptide that blocks N-type calcium channels and is antihyperalgesic after intrathecal (IT) delivery. We here characterize the spinal kinetics of IT bolus and infused ziconotide in dog. EXPERIMENTAL APPROACH: Male beagle dogs (N= 5) were prepared with chronic IT lumbar injection and cerebrospinal fluid (LCSF) sampling catheters connected to vest-mounted pumps. Each dog received the following: 1) IT bolus ziconotide (10 µg + 1 µCi (3) H-inulin); 2) IT infusion for 48 hours of ziconotide (1 µg/100 µL/hour); 3) IT infusion for 48 hours of ziconotide (5 µg/100 µL/hour); and 4) intravenous injection of ziconotide (0.1 mg/kg). After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T(1/2-α/β) = 0.14 and 1.77 hours, and inulin T(1/2-α/β) = 0.16 and 3.88 hours, respectively). The LCSF : plasma ziconotide concentration ratio was 20,000:1 at 30 min and 30:1 at eight hours. IT infusion of 1 and then 5 µg/hour resulted in LCSF concentrations that peaked by eight hours and remained stable at 343 and 1380 ng/mL, respectively, to the end of the 48-hour infusions. Terminal elimination T(1/2) after termination of continuous infusion was 2.47 hours. Ziconotide LCSF : cisternal CSF : plasma concentration ratios after infusion of 1 and 5 µg/hour were 1:0.017:0.001 and 1:0.015:0.003, respectively. IT infusion of ziconotide at 1 µg/hour inhibited thermal skin twitch by 24 hours and produced modest trembling, ataxia, and decreased arousal. Effects continued through the 48-hour infusion period, increased in magnitude during the subsequent 5 µg/hour infusion periods, and disappeared after drug clearance. CONCLUSIONS AND IMPLICATIONS: After IT bolus or infusion, ziconotide displays linear kinetics that are consistent with a hydrophilic molecule of approximately 2500 Da that is cleared slightly more rapidly than inulin from the LCSF. Behavioral effects were dose dependent and reversible.

Indexed as

AnimalsArea Under CurveArousalBlood PressureCalcium Channel BlockersDogsDose-Response Relationship, DrugHeart RateInfusions, ParenteralInjections, SpinalMaleMotor ActivityNociceptionomega-ConotoxinsPharmacokineticsSkinCalcium Channel Blockersomega-Conotoxinsziconotide

Identifiers

PMID22748108
PMCPMC3514653
OpenAlexW2109982684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.